RNF43 and pancreatic adenocarcinoma: For example, genome-scale pooled CRISPR screening technology was applied to identify vulnerabilities in RNF43(ring finger protein-43)-mutant pancreatic adenocarcinomas, finding FZD5 (frizzled class receptor 5) as a common vulnerability that can be exploited therapeutically [50].